A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer
Status:
Completed
Trial end date:
2001-01-01
Target enrollment:
Participant gender:
Summary
Bolus PSC 833 is administered on Day 1 simultaneously with initiation of 24 hour continuous
infusion of PSC 833, followed by another continuous infusion lasting an additional 6 days. To
ensure the safety of a 7 day infusion of PSC 833, one patient is treated for 5 days and a
second for 6 days, before the first cohort is enrolled.
Vinblastine is administered in escalating doses on days 2-5. At least 3 patients are entered
at each dose level. The MTD will be defined as the dose immediately below that at which 2
patients experience dose limiting toxicity.
Treatment continues every 28 days.